Science Corp's Brain Implant Restores Vision in 81% of Blind Trial Patients
Key Takeaways
- ▸Science Corp's PRIMA retinal implant restored clinically meaningful vision in 81% of blind trial patients with age-related macular degeneration, with results published in the New England Journal of Medicine
- ▸The 2mm chip, half the thickness of a human hair, is surgically implanted beneath the retina and converts infrared light into electrical signals to restore reading ability
- ▸Science Corporation raised $230M at a $1.5B valuation and has submitted its application to the FDA, positioning it as the first BCI company potentially bringing vision restoration to market
Summary
Science Corporation has achieved a breakthrough in vision restoration with its PRIMA retinal implant, successfully restoring clinically meaningful vision in 26 of 32 blind trial patients (81%) suffering from age-related macular degeneration (AMD). The results, published in the New England Journal of Medicine, showed patients gained an average of five full lines on an eye chart, with 84% able to read letters, numbers, and words again. The 2mm chip, just 30 micrometers thin, is surgically placed beneath the retina where it converts infrared light into electrical signals that stimulate remaining retinal cells.
The company, founded by Max Hodak (former president and co-founder of Neuralink), has raised $230 million in Series C funding at a $1.5 billion valuation, with Y Combinator among its investors. The FDA is currently reviewing the application for market approval. The PRIMAvera trial enrolled 38 participants with geographic atrophy from AMD, a leading cause of irreversible blindness. While 26 serious adverse events occurred across 19 participants, 81% occurred within two months of surgery and 95% of those resolved within two months, with natural peripheral vision remaining unaffected.
Patients like Sheila Irvine, who described her AMD-ravaged vision as "two black discs" blocking her central sight, regained the ability to read prescription labels, crossword puzzles, and engage in activities that had been impossible for years. According to Dr. Mahi Muqit of Moorfields Eye Hospital, this represents "a new era" in artificial vision, marking the first time blind patients have achieved meaningful central vision restoration at this level of acuity. The technology positions Science Corp as potentially the first brain-computer interface company to bring a vision restoration product to market.
- Patients gained an average of five lines on eye charts, with 84% able to read again after years of blindness from geographic atrophy
- Founded by former Neuralink president Max Hodak, the technology represents the first successful restoration of central vision in patients with advanced AMD
Editorial Opinion
Science Corp's PRIMA implant represents a watershed moment for both brain-computer interfaces and medical AI applications. Unlike the more speculative consumer BCIs capturing headlines, this technology solves a concrete, devastating medical problem with peer-reviewed efficacy data — an 81% success rate in restoring reading vision to the blind is nothing short of revolutionary. The fact that it's reaching FDA review before flashier competitors speaks to focused execution on real medical needs rather than futuristic hype. This could be the proof point that legitimizes the entire BCI industry beyond research labs and into clinical medicine.
